We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?
- Authors
Wang, Diane D.; Yu, Yanke; Fukuhara, Kei; Liu, Yuwang; Park, So‐Young; Parivar, Kourosh
- Abstract
The current regulatory path for new drug registration in East Asian countries has led to significant delay of the new medicines in these countries. A unified regulatory path and allowance of mutual usage of clinical data in East Asian countries would lead to cost saving in drug development and expedite the new drug registration in these countries. The objectives of the present analysis are to compare the approval dates of a selection of products developed by Pfizer in the United States and East Asian countries (China, Japan, Korea) and compare the pharmacokinetics and recommended doses of these products in East Asian countries. Eighteen products (20 drugs, 2 products with 2 combination drugs) with exposure data available in at least 2 of the 3 East Asian countries across different therapeutic areas were included in the analyses. The results showed that most products had delayed approval in East Asian countries (up to 8 years) after US or EU approval. No distinct differences were observed in the drug exposure and recommended doses for the selected products in East Asian countries. These results together with literature data of genetic similarity of the East Asian populations support the mutual usage of the clinical data in the East Asian countries for expedited regulatory submission and approval.
- Subjects
UNITED States; DRUG approval laws; DRUG laws; PATIENT safety; RESEARCH funding; INVESTIGATIONAL drugs; EAST Asians; DESCRIPTIVE statistics; PEDIATRICS; DOSE-effect relationship in pharmacology; PHARMACOKINETICS; DRUG efficacy; DRUG development; MANAGEMENT of medical records; COMPARATIVE studies
- Publication
Journal of Clinical Pharmacology, 2024, Vol 64, Issue 5, p609
- ISSN
0091-2700
- Publication type
Article
- DOI
10.1002/jcph.2394